| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/29/2005 | US6872554 For therapy of Alzheimer's disease; immunization |
| 03/29/2005 | US6872550 Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens |
| 03/29/2005 | US6872548 Polypeptide for use in animal models associated with human therapeutics |
| 03/29/2005 | US6872547 Functional balanced-lethal host-vector systems |
| 03/29/2005 | US6872520 Peptide for use in the detection of viral infection and diseases |
| 03/29/2005 | US6872399 Dermatomycosis vaccine |
| 03/29/2005 | US6872398 Conjugate vaccine against gram-negative bacterial infections |
| 03/29/2005 | US6872395 Viruses comprising mutant ion channel protein |
| 03/29/2005 | US6872393 Polyalkylene oxide-modified single chain polypeptides |
| 03/29/2005 | US6872386 Immunization of aquatic animals against infectious diseases |
| 03/29/2005 | US6872385 Adjuvant preparation for the induction of specific immunity |
| 03/29/2005 | CA2425745C Expression of exogenous polynucleotide sequences in a vertebrate |
| 03/29/2005 | CA2372409C Delivery of macromolecules into cells |
| 03/29/2005 | CA2301732C Therapeutic combinations |
| 03/29/2005 | CA2240541C Stabilisers for live vaccines |
| 03/29/2005 | CA2170772C Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
| 03/29/2005 | CA2049287C Expression of exogenous polynucleotide sequences in a vertebrate |
| 03/29/2005 | CA1341477C Method of reducing immunoglobulin e responses |
| 03/24/2005 | WO2005026733A1 Method and device for detecting feline immunodeficiency virus |
| 03/24/2005 | WO2005026388A2 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 03/24/2005 | WO2005026370A2 Multi-antigen vectors for melanoma |
| 03/24/2005 | WO2005026360A1 Cellular model of tauopathies for lead identification and drug discovery |
| 03/24/2005 | WO2005026333A1 Technique for suspension culture of adhesive cells using protease and method of producing virus with the use of the cells as host |
| 03/24/2005 | WO2005026318A2 Methods and compositions for producing antigenic responses |
| 03/24/2005 | WO2005026269A1 Microorganism coating components, coatings, and coated surfaces |
| 03/24/2005 | WO2005026203A2 Dna promoters and anthrax vaccines |
| 03/24/2005 | WO2005026200A2 Lawsonia intracellularis subunit vaccine |
| 03/24/2005 | WO2005026195A1 Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive aspergillosis |
| 03/24/2005 | WO2005025624A2 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 03/24/2005 | WO2005025619A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 03/24/2005 | WO2005025618A2 Treatment of rheumatoid arthritis with cd99 antagonists |
| 03/24/2005 | WO2005025614A2 Improvements in vaccination |
| 03/24/2005 | WO2005025613A1 Methods of identifying biomolecular targets for diagnosis and therapy |
| 03/24/2005 | WO2005025612A1 Vaccines |
| 03/24/2005 | WO2005025611A1 Inhibitors of pace4 for the treatment of arthritis |
| 03/24/2005 | WO2005025518A2 Inhibition of inward sodium currents in cancer |
| 03/24/2005 | WO2005025516A2 Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| 03/24/2005 | WO2005025509A2 Methods and materials for treating autoimmune diseases and conditions |
| 03/24/2005 | WO2005025494A2 Vaccine immunotherapy for immune suppressed patients |
| 03/24/2005 | WO2005012493A3 Anti-cd19 antibodies |
| 03/24/2005 | WO2005011614A3 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 03/24/2005 | WO2005000886A3 T24 antigen for immunodiagnosis of taenia solium cysticercosis |
| 03/24/2005 | WO2005000348A3 Vaccines inducing nkt-cell and toll-like-receptor activation |
| 03/24/2005 | WO2004111270A3 Differential gene expression in schizophrenia |
| 03/24/2005 | WO2004105681A3 Cd4+ human papillomavirus (hpv) epitopes |
| 03/24/2005 | WO2004103400A3 Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines |
| 03/24/2005 | WO2004101766A3 Grp94-based compositions and methods of use thereof |
| 03/24/2005 | WO2004100985A3 Materials and methods for immunizing against fiv infection |
| 03/24/2005 | WO2004098509A3 Compositions for inducing immune responses |
| 03/24/2005 | WO2004085466A3 Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use |
| 03/24/2005 | WO2004084839A3 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
| 03/24/2005 | WO2004084836A3 Methods for treating taxol-induced gut disorder |
| 03/24/2005 | WO2004076644A3 A composition for delivering an agent to a target cell and uses thereof |
| 03/24/2005 | WO2004075829A3 Adjuvanted influenza vaccine |
| 03/24/2005 | WO2004074318A3 Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof. |
| 03/24/2005 | WO2004073641A3 Induced activation in dendritic cells |
| 03/24/2005 | WO2004072262A3 Cultured cd14+ antigen presenting cells |
| 03/24/2005 | WO2004071387A3 Hsp60 from arthrobacter |
| 03/24/2005 | WO2004069860A3 Isg15-conjugated proteins |
| 03/24/2005 | WO2004067554A3 Compositions and methods of tolerizing a primate to an antigen |
| 03/24/2005 | WO2004065409A3 Peptide mimotopes of lipooligosaccharide from nontypeable haemophilus influenzae as vaccines |
| 03/24/2005 | WO2004064788A3 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 03/24/2005 | WO2004059285A3 Tumor killing/tumor regression using cxcr4 antagonists |
| 03/24/2005 | WO2004052933A3 Peptide oligomers for use as hiv vaccines |
| 03/24/2005 | WO2004050856A3 Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| 03/24/2005 | WO2004047761A3 Mbcats as modifiers of the beta-catenin pathway and methods of use |
| 03/24/2005 | WO2004043338A3 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents |
| 03/24/2005 | WO2004020406A3 Variants of vibrio cholerae o1 biotype e1 tor with attributes of classical biotype |
| 03/24/2005 | WO2004016228A3 HTLV-I p30II AND p12I PROTEINS AS THERAPEUTIC TARGETS IN HTVL-I INFECTED INDIVIDUALS |
| 03/24/2005 | WO2003105875A8 Immunostimulator having antineoplastic action and method for producing said immunostimulator |
| 03/24/2005 | WO2003104407A3 T cell receptor cdr3 sequences and methods for detection |
| 03/24/2005 | WO2003103478A3 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs |
| 03/24/2005 | WO2003090687A9 Using heat shock proteins to increase immune response |
| 03/24/2005 | WO2003087134A3 G-protein coupled receptor ligands and methods |
| 03/24/2005 | WO2002092759A9 Molecules for disease detection and treatment |
| 03/24/2005 | WO2001068858A8 Human g protein-coupled receptors |
| 03/24/2005 | US20050065325 Monoclonal antibody for use as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders |
| 03/24/2005 | US20050065321 Cytokine receptor (Zcytor16) for use as tool in prevention and treatment of cell proliferative and nervous system disorders |
| 03/24/2005 | US20050065320 Mutated env gene, mutated env glycoprotein and the use thereof |
| 03/24/2005 | US20050065192 Synergistic mixture of methotrexate and integrin antigen or antibody |
| 03/24/2005 | US20050065106 Plasmid vector comprising nucleotide sequence encoding exterior membrane protein of chlamydia strains; gene expression; veccine |
| 03/24/2005 | US20050064594 Transgenic liver cell for use as tool in diagnosis, prevention and treatment of viral diseases; viricides and receptor binding activity |
| 03/24/2005 | US20050064572 Lipid kinase |
| 03/24/2005 | US20050064543 Secreted proteins |
| 03/24/2005 | US20050064541 For immunoregulation and/or treatment of inflammation; muteins, |
| 03/24/2005 | US20050064527 Identifying modulator of activity of newly identified multiple antibiotic resistance (mar) locus regulated (NIMR) gene products; microbiocides; bactericides |
| 03/24/2005 | US20050064522 EG-VEGF nucleic acids and polypeptides and methods of use |
| 03/24/2005 | US20050064499 Expression vector coding nucleotide sequences for use in identifying modulators for prevention and treatment of cell proliferative disorders |
| 03/24/2005 | US20050064493 Antibodies specific for vascular endothelial growth factor-B and DNA coding therefor |
| 03/24/2005 | US20050064475 Using type II membrane glycoprotein (4F2hc) as tool in identifying modulator which inhibit transcription in tumor cells; gene expresion inhibition and antitumors agents |
| 03/24/2005 | US20050064464 Optimization of immunomodulatory properties of genetic vaccines |
| 03/24/2005 | US20050064458 Nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatnment of cell proliferative, nervous system, metabolic and inflammatory disorders |
| 03/24/2005 | US20050064445 Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 03/24/2005 | US20050064440 Using single nucleotide polymorphism in contactin-2 (CNTN-2) and kinesin-7 (CENP-E) genes as diagnostic indicators of cell proliferative disorders; antitumor agents; ribozymes and tumor treatment; RNA interference |
| 03/24/2005 | US20050064409 Chp for use as marker for sepsis-type inflammatory diseases |
| 03/24/2005 | US20050064404 Regulation of human serotonin-like g protein-coupled receptor |
| 03/24/2005 | US20050064392 Expression vector comprising nucleotide sequences coding viral envelope proteins for use as tool in developing genetic vaccines to prevent, block and/or treat viral infection/disease |
| 03/24/2005 | US20050064391 Lectin compositions and methods for modulating an immune response to an antigen |
| 03/24/2005 | US20050064389 Chimeric lyssavirus nucleic acids and polypeptides |
| 03/24/2005 | US20050063995 mammalian tumor cells having been treated ex vivo by stressing with an oxidative environment such as ozone or oxygen and UV light simultaneously, to render the tumor cells effective to elicit an immune response to a melanoma, colon carcinoma or breast cancer tumor |